Birk Möller,Lena-Luise Becker,Afshin Saffari,Alexandra Afenjar,Emanuele G Coci,Rachel Williamson,Catherine Ward-Melver,Marc Gibaud,Lucie Sedláčková,Petra Laššuthová,Zuzana Libá,Markéta Vlčková,Nancy William,Eric W Klee,Ralitza H Gavrilova,Jonathan Lévy,Yline Capri,Mena Scavina,Robert Walter Körner,Zaheer Valuvullah,Claudia Weiß,Greta Marit Möller,Moritz Thiel,Margje Sinnema,Erik-Jan Kamsteeg,Sandra Donkervoort,Veronique Duboc,Khaoula Zaafrane-Khachnaoui,Nour Elkhateeb,Laila Selim,Henri Margot,Victor Marin,Claire Beneteau,Bertrand Isidor,Benjamin Cogne,Boris Keren,Benno Küsters,Alan H Beggs,Casie A Genetti,Joost Nicolai,Jörg Dötsch,Anne Koy,Carsten G Bönnemann,Maja von der Hagen,Jürgen-Christoph von Kleist-Retzow,Nicol Voermans,Heinz Jungbluth,Hormos Salimi Dafsari

Abstract:Intracellular trafficking involves an intricate machinery of motor complexes including the dynein complex to shuttle cargo for autophagolysosomal degradation. Deficiency in dynein axonemal chains as well as cytoplasmic light and intermediate chains have been linked with ciliary dyskinesia and skeletal dysplasia. The cytoplasmic dynein 1 heavy chain protein (DYNC1H1) serves as a core complex for retrograde trafficking in neuronal axons. Dominant pathogenic variants in DYNC1H1 have been previously implicated in peripheral neuromuscular disorders (NMD) and neurodevelopmental disorders (NDD). As heavy-chain dynein is ubiquitously expressed, the apparent selectivity of heavy-chain dyneinopathy for motor neuronal phenotypes remains currently unaccounted for. Here, we aimed to evaluate the full DYNC1H1 -related clinical, molecular and imaging spectrum, including multisystem features and novel phenotypes presenting throughout life. We identified 47 cases from 43 families with pathogenic heterozygous variants in DYNC1H1 (aged 0-59 years) and collected phenotypic data via a comprehensive standardized survey and clinical follow-up appointments. Most patients presented with divergent and previously unrecognized neurological and multisystem features, leading to significant delays in genetic testing and establishing the correct diagnosis. Neurological phenotypes include novel autonomic features, previously rarely described behavioral disorders, movement disorders, and periventricular lesions. Sensory neuropathy was identified in nine patients (median age of onset 10.6 years), of which five were only diagnosed after the second decade of life, and three had a progressive age-dependent sensory neuropathy. Novel multisystem features included primary immunodeficiency, bilateral sensorineural hearing loss, organ anomalies, and skeletal manifestations, resembling the phenotypic spectrum of other dyneinopathies. We also identified an age-dependent biphasic disease course with developmental regression in the first decade and, following a period of stability, neurodegenerative progression after the second decade of life. Of note, we observed several cases in whom neurodegeneration appeared to be prompted by intercurrent systemic infections with double-stranded DNA viruses (Herpesviridae) or single-stranded RNA viruses (Ross-River fever, SARS-CoV-2). Moreover, the disease course appeared to be exacerbated by viral infections regardless of age and/or severity of NDD manifestations, indicating a role of dynein in anti-viral immunity and neuronal health. In summary, our findings expand the clinical, imaging, and molecular spectrum of pathogenic DYNC1H1 variants beyond motor neuropathy disorders and suggest a life-long continuum and age-related progression due to deficient intracellular trafficking. This study will facilitate early diagnosis and improve counselling and health surveillance of affected patients.

Assessing age of onset and clinical symptoms over time in patients with heterozygous pathogenic DHDDS variants

Analysis of Clinical Phenotype and CGH1 Gene Mutations in a Family Affected with Dopa-Responsive Dystonia

Phenotype of heterozygous variants of dehydrodolichol diphosphate synthase

(CAG)n loci as genetic modifiers of age-at-onset in patients with Machado-Joseph disease from mainland China.

DHDDS-related disease; biallelic missense novel variant causing major severity with an early-onset epilepsy and hyperkinetic movement disorder

The expanding clinical and genetic spectrum of DYNC1H1 -related disorders

Case report: Identification of a recurrent pathogenic DHDDS mutation in Chinese family with epilepsy, intellectual disability and myoclonus

DHDDS and NUS1: A Converging Pathway and Common Phenotype

PCDH19-related epilepsy in mosaic males: The phenotypic implication of genotype and variant allele frequency

A systematic review and meta-analysis of 271 PCDH19-variant individuals identifies psychiatric comorbidities, and association of seizure onset and disease severity

Mono and biallelic variants in cause severe neurodevelopmental disorders

A Novel Variant of the CHD2 Gene Associated With Developmental Delay and Myoclonic Epilepsy

Bi-allelic HPDL Variants Cause a Neurodegenerative Disease Ranging from Neonatal Encephalopathy to Adolescent-Onset Spastic Paraplegia.

Expanding the phenotypic spectrum for CDK8‐related disease: A case report

Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome

Genotype–phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders

Genetic Variants and Phenotype Analysis in a Five-Generation Chinese Pedigree with PCDH19 Female-Limited Epilepsy.

Mutation in ZDHHC15 Leads to Hypotonic Cerebral Palsy, Autism, Epilepsy, and Intellectual Disability

A standardized patient-centered characterization of the phenotypic spectrum of PCDH19 girls clustering epilepsy

Novel Homozygous Truncating Variant Widens the Spectrum of Early-Onset Multisystemic SYNE1 Ataxia

Clinical and genetic profile of Chinese children with Danon disease: A single-center retrospective cohort study